Guardant Gets European Approval for Guardant360 as Companion Diagnostic for AstraZeneca's Etcamah in Breast Cancer

MT newswire2026/10/08 20:42

04:42 PM EDT, 10/08/2026 (MT Newswires) -- Guardant Health's (GH) Guardant360 CDx has received CE-marking in Europe as a companion diagnostic to identify people with advanced estrogen receptor-positive breast cancer who may benefit from treatment with AstraZeneca's (AZN) Etcamah, the company said Thursday. The move follows regulatory clearance of Guardant360 CDx blood test as a companion diagnostic for Etcamah in the US and Japan, the company said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq

Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.

智通财经•2026/11/09 06:12

UniCredit: Third-quarter net profit reaches 3.26 billion euros, exceeding expectations

格隆汇•2026/11/09 06:11

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45